Preclinical studies suggest that roprinole may be a neuroprotective in Parkinson’s disease. A study using F-dopa positron emission tomography showed that there was a slower loss of dopamine storage with roprinole compared to levodopa. More to come as this research develops. Back in October we did a brief comparing requip and levodopa, to access that click here.

This entry was posted on Monday, February 4th, 2008 at 9:00 pm and is filed under Drugs, General. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.